Abstract
OBJECTIVE: To compare the efficacy and safety of a 7-day course of treatment with oral grepafloxacin, 400 mg once daily, and oral doxycycline, 100 mg twice daily, in patients with chlamydial cervicitis. METHODS: Women aged 18 years or older attending 17 sexually transmitted disease clinics in the United States who had clinical signs of mucopurulent cervicitis or who had a recent positive culture or nonculture test for Chlamydia trachomatis or who had contact with a male partner with a positive culture for C. trachomatis were enrolled into this randomized, double-blind, active-controlled clinical study. The diagnosis of chlamydial cervicitis was based on culture for C. trachomatis. Patients were randomized to receive a 7-day course of treatment with either oral grepafloxacin, 400 mg once daily, or oral doxycycline, 100 mg twice daily. Response to therapy was assessed 3-8 days and 21-28 days after completion of treatment. The primary measure of efficacy was eradication of C. trachomatis at the 21-28 day follow-up visit. Clinical success, defined as improvement or complete resolution of the signs and symptoms of cervicitis, was a secondary measure of efficacy. RESULTS: Of the 451 female patients enrolled, 228 received grepafloxacin and 223 received doxycycline. In all, 154/451 (35%) patients were evaluable at the 21-28 day follow-up (81 who received grepafloxacin and 73 who received doxycycline). Microbiologic and clinical success rates demonstrated the equivalence of the two treatments. The C. trachomatis eradication rates were 96.3% (78/81) and 98.6% (72/73) for patients receiving grepafloxacin or doxycycline, respectively. The two study drugs were also equivalent in resolving clinical signs and symptoms, with clinical success rates of 88.9% (64/72) and 89.5% (51/57) for patients treated with grepafloxacin and doxycycline, respectively. Both drugs were well tolerated, with 47% of patients receiving grepafloxacin and 46% of patients receiving doxycycline experiencing drug-related adverse events, none of which was serious. CONCLUSIONS: Seven days of treatment with oral grepafloxacin, 400 mg once daily, was as effective as 7 days of treatment with oral doxycycline, 100 mg twice daily, in patients with cervicitis caused by C. trachomatis. Both agents were well tolerated and had comparable safety profiles. Grepafloxacin's once-daily dosing regimen may offer advantages in terms of patient compliance.
Full Text
The Full Text of this article is available as a PDF (568.9 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bell T. A., Stamm W. E., Wang S. P., Kuo C. C., Holmes K. K., Grayston J. T. Chronic Chlamydia trachomatis infections in infants. JAMA. 1992 Jan 15;267(3):400–402. [PubMed] [Google Scholar]
- Brunham R. C., Maclean I. W., Binns B., Peeling R. W. Chlamydia trachomatis: its role in tubal infertility. J Infect Dis. 1985 Dec;152(6):1275–1282. doi: 10.1093/infdis/152.6.1275. [DOI] [PubMed] [Google Scholar]
- Eisen S. A., Miller D. K., Woodward R. S., Spitznagel E., Przybeck T. R. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990 Sep;150(9):1881–1884. [PubMed] [Google Scholar]
- Kassler W. J., Cates W., Jr The epidemiology and prevention of sexually transmitted diseases. Urol Clin North Am. 1992 Feb;19(1):1–12. [PubMed] [Google Scholar]
- Kenny G. E., Cartwright F. D. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116. Antimicrob Agents Chemother. 1993 Aug;37(8):1726–1727. doi: 10.1128/aac.37.8.1726. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Matsuda S. Clinical experience with OPC-17116 in the treatment of gynaecological infections and its penetration into gynaecological tissues. Japanese Collaborative Study Group of OPC-17116 in Gynaecology. Drugs. 1995;49 (Suppl 2):395–398. doi: 10.2165/00003495-199500492-00111. [DOI] [PubMed] [Google Scholar]
- Roblin P. M., Montalban G., Hammerschlag M. R. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1994 Jun;38(6):1402–1403. doi: 10.1128/aac.38.6.1402. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schachter J. Chlamydial infections (second of three parts). N Engl J Med. 1978 Mar 2;298(9):490–495. doi: 10.1056/NEJM197803022980905. [DOI] [PubMed] [Google Scholar]
- Taira K., Koga H., Kohno S. Accumulation of a newly developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1993 Sep;37(9):1877–1881. doi: 10.1128/aac.37.9.1877. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zenilman J. M., Neumann T., Patton M., Reichart C. Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin against 200 isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1993 Oct;37(10):2244–2246. doi: 10.1128/aac.37.10.2244. [DOI] [PMC free article] [PubMed] [Google Scholar]